Stockscreener 앱 받기
10.40
0.87%
0.09
전일 마감가:
$10.31
열려 있는:
$10.31
하루 거래량:
1.00M
Relative Volume:
0.47
시가총액:
$1.43B
수익:
$62.04M
순이익/손실:
$-533.34M
주가수익비율:
-2.6531
EPS:
-3.92
순현금흐름:
$-473.07M
1주 성능:
-2.16%
1개월 성능:
+41.69%
6개월 성능:
+2.36%
1년 성능:
+10.64%
1일 변동 폭
$10.14
$10.64
1주일 범위
$10.09
$11.02
52주 변동 폭
$6.56
$14.45
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
VIR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.40 | 1.43B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
HC Wainwright Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology appoints new Chief Technical Officer By Investing.com - Investing.com Canada
Vir Biotechnology Inc. (VIR) Stock Overview and Recent Developments – Market - HPBL
Vir Biotechnology Shares Surge After Opening Higher: A Market Overview – Market - HPBL
Vir Biotechnology, Inc. Announces Executive Changes -January 30, 2025 at 07:51 am EST - Marketscreener.com
Vir Biotechnology appoints new Chief Technical Officer - Investing.com
Vir Biotechnology Inc. (VIR) Announces CTO Departure - StreetInsider.com
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
Vir Biotechnology Phase 1 Data on Dual-Masked T-Cell Engagers (TCEs) – Market - HPBL
Vir Biotechnology (NASDAQ:VIR) Shares Down 3.8%Should You Sell? - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Up 6.3%What's Next? - MarketBeat
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now - Insider Monkey
Hepatitis B Virus Infection Clinical and Non-Clinical Studies, - openPR
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
JP Morgan Week 2025 – Marianne De Backer - pharmaphorum
What is Leerink Partnrs’ Forecast for VIR Q1 Earnings? - Defense World
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) PT at $34.83 - Defense World
Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4%Here's What Happened - MarketBeat
Q1 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
JPMorgan Chase & Co. Has $8.14 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Q2 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $34.83 - MarketBeat
Leerink Partners Boosts Vir Biotechnology (NASDAQ:VIR) Price Target to $20.00 - MarketBeat
Nordea Investment Management AB Sells 286,600 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 - MSN
Vir Biotech upgraded at Morgan Stanley on cancer drug data - MSN
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - MSN
Morgan Stanley Doubles Vir Biotechnology Price ForecastHere's Why - AOL
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright - MarketBeat
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates - MSN
Morgan Stanley Upgrades Vir Biotechnology (VIR) - MSN
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58% - GuruFocus.com
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong? (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology (NASDAQ:VIR) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 By Investing.com - Investing.com Canada
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies - Yahoo Finance
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology S - GuruFocus.com
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock - Yahoo Finance
Vir Biotechnology stock soars 58%: Is it still a buy? - Dataconomy
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighHere's Why - MarketBeat
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):